Review



v501-016  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Merck & Co v501-016
    Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials
    V501 016, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v501-016/gardasil9/pmc05116857-137-22-21
    Average 90 stars, based on 1 article reviews
    v501-016 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials"

    Article Title: Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials

    Journal: Basic and Clinical Andrology

    doi: 10.1186/s12610-016-0042-7

    Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials
    Figure Legend Snippet: Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials

    Techniques Used: Injection, Infection

    Related Articles

    Selection:

    Article Title: Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials
    Article Snippet: The pregnancy/ perinatal outcomes from the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I (Merck V501-013), FUTURE II (Merck V501-015), Merck V501-016, and Merck V501-018 RCTs were combined in the Appendix in the FUTURE II study (Merck V501-016, 018 did not meet selection criteria in this literature review) [ ].

    Injection:

    Article Title: Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials
    Article Snippet: The pregnancy/ perinatal outcomes from the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I (Merck V501-013), FUTURE II (Merck V501-015), Merck V501-016, and Merck V501-018 RCTs were combined in the Appendix in the FUTURE II study (Merck V501-016, 018 did not meet selection criteria in this literature review) [ ].

    Infection:

    Article Title: Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials
    Article Snippet: The pregnancy/ perinatal outcomes from the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I (Merck V501-013), FUTURE II (Merck V501-015), Merck V501-016, and Merck V501-018 RCTs were combined in the Appendix in the FUTURE II study (Merck V501-016, 018 did not meet selection criteria in this literature review) [ ].



    Similar Products

    v501-016  (Merck & Co)
    90
    Merck & Co v501-016
    Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials
    V501 016, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v501-016/gardasil9/pmc05116857-137-22-21
    Average 90 stars, based on 1 article reviews
    v501-016 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials

    Journal: Basic and Clinical Andrology

    Article Title: Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials

    doi: 10.1186/s12610-016-0042-7

    Figure Lengend Snippet: Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials

    Article Snippet: The pregnancy/ perinatal outcomes from the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I (Merck V501-013), FUTURE II (Merck V501-015), Merck V501-016, and Merck V501-018 RCTs were combined in the Appendix in the FUTURE II study (Merck V501-016, 018 did not meet selection criteria in this literature review) [ ].

    Techniques: Injection, Infection